Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.creator | Sánchez-Lorenzo, M. L. (María Luisa) | - |
dc.creator | Custodio, A. (Ana) | - |
dc.creator | Carmona-Bayonas, A. (Alberto) | - |
dc.creator | Jiménez-Fonseca, P. (Paula) | - |
dc.creator | Viudez, A. (Antonio) | - |
dc.creator | Hernández, R. (Raquel) | - |
dc.creator | Cano, J. M. (Juana María) | - |
dc.creator | Echavarría, I. (Isabel) | - |
dc.creator | Pericay, C. (Carles) | - |
dc.creator | Mangas, M. (Monserrat) | - |
dc.creator | Visa, L. (Laura) | - |
dc.creator | Buxó, E. (Elvira) | - |
dc.creator | García-García, T. (Teresa) | - |
dc.creator | Rodríguez-Palomo, A. (Alberto) | - |
dc.creator | Álvarez-Manceñido, F. (Felipe) | - |
dc.creator | Lacalle, A. (Alejandra) | - |
dc.creator | Macías-Declara, I. (Ismael) | - |
dc.creator | Azkarate, A. (Aitor) | - |
dc.creator | Ramchandani, A. (Avinash) | - |
dc.creator | Fernández-Montes, A. (Ana) | - |
dc.creator | López, C. (Carolina) | - |
dc.creator | Longo, F. | - |
dc.creator | Sanchez-Bayona, R. (Rodrigo) | - |
dc.creator | Limón, M. L. (María-Luisa) | - |
dc.date.accessioned | 2024-02-07T12:54:28Z | - |
dc.date.available | 2024-02-07T12:54:28Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Sánchez-Lorenzo, M. L. (María Luisa); Custodio, A. (Ana); Carmona-Bayonas, A. (Alberto); et al. "Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab". British Journal of Cancer. 116, 2017, 1526 - 1535 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10171/68882 | - |
dc.description.abstract | Background: To develop and validate a nomogram and web-based calculator to predict overall survival (OS) in Caucasian-advanced oesophagogastric adenocarcinoma (AOA) patients undergoing first-line combination chemotherapy. Methods: Nine hundred twenty-four AOA patients treated at 28 Spanish teaching hospitals from January 2008 to September 2014 were used as derivation cohort. The result of an adjusted-Cox proportional hazards regression was represented as a nomogram and web-based calculator. The model was validated in 502 prospectively recruited patients treated between October 2014 and December 2016. Harrell's c-index was used to evaluate discrimination. Results: The nomogram includes seven predictors associated with OS: HER2-positive tumours treated with trastuzumab, Eastern Cooperative Oncology Group performance status, number of metastatic sites, bone metastases, ascites, histological grade, and neutrophil-to-lymphocyte ratio. Median OS was 5.8 (95% confidence interval (CI), 4.5–6.6), 9.4 (95% CI, 8.5–10.6), and 14 months (95% CI, 11.8–16) for high-, intermediate-, and low-risk groups, respectively (P<0.001), in the derivation set and 4.6 (95% CI, 3.3–8.1), 12.7 (95% CI, 11.3–14.3), and 18.3 months (95% CI, 14.6–24.2) for high-, intermediate-, and low-risk groups, respectively (P<0.001), in the validation set. The nomogram is well-calibrated and reveals acceptable discriminatory capacity, with optimism-corrected c-indices of 0.618 (95% CI, 0.591–0.631) and 0.673 (95% CI, 0.636–0.709) in derivation and validation groups, respectively. The AGAMENON nomogram outperformed the Royal Marsden Hospital (c-index=0.583; P=0.00046) and Japan Clinical Oncology Group prognostic indices (c-index=0.611; P=0.03351). Conclusions: We developed and validated a straightforward model to predict survival in Caucasian AOA patients initiating first-line polychemotherapy. This model can contribute to inform clinical decision-making and optimise clinical trial design. | es_ES |
dc.language.iso | eng | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | OS: HER2-positive tumours | es_ES |
dc.subject | Eastern Cooperative Oncology Group | es_ES |
dc.subject | Confidence interval | es_ES |
dc.subject | AGAMENON | es_ES |
dc.subject | Royal Marsden Hospital | es_ES |
dc.subject | Japan Clinical Oncology Group prognostic indices | es_ES |
dc.subject | Median OS | es_ES |
dc.title | Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://www.nature.com/articles/bjc2017122 | es_ES |
dc.editorial.note | © 2017 Cancer Research UK. All rights reserved 0007 – 0920/17 | es_ES |
dadun.citation.endingPage | 1535 | es_ES |
dadun.citation.publicationName | British Journal of Cancer | es_ES |
dadun.citation.startingPage | 1526 | es_ES |
dadun.citation.volume | 116 | es_ES |
Ficheros en este ítem:
Estadísticas e impacto
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.